Related Experiment Video
Updated: Jan 11, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Effectiveness and safety of finerenone in IgA nephropathy patients
Kuipeng Yu1,2, Dengren Li1, Xin Fan1
1Department of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Background And Hypothesis:
Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis and a common cause of end-stage kidney disease. This study aimed to evaluate the effectiveness and safety of finerenone in combination with an angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker (ACEI/ARB) regimen in IgAN patients.
Methods:
Our study was a single-center, observational, retrospective clinical study. Fifty-two primary IgAN patients were added. Patients were divided into two groups: the finerenone combined with ACEI/ARB group and the ACEI/ARB group. The primary endpoint was treatment response, defined as the percentage change in urinary protein/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) from baseline to 6 months. The secondary endpoint was the safety of finerenone, with adverse events recorded during treatment. Clinical data were collected from IgAN patients.
Results:
Of the 52 IgAN patients enrolled, 19 were in the finerenone combined with ACEI/ARB group and 33 in the ACEI/ARB group. At 6 months, the percentage change in UPCR was significantly greater in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group [-52.10% (interquartile range, IQR -65.71%, -6.12%) vs -21.25% (IQR -39.84%, -6.19%); P = .04]. Furthermore, the UPCR was lower in the finerenone combined with ACEI/ARB group [0.41 g/g (IQR 0.30, 0.72) vs 0.68 g/g (IQR 0.49, 1.10); P = .024]. Serum albumin levels were higher in the finerenone combined with ACEI/ARB group than in the ACEI/ARB group (44.84 ± 2.35 g/L vs 42.96 ± 3.27 g/L; P = .033). No significant changes in eGFR were observed between the groups (P = .091). The response rate was significantly higher in the finerenone combined with ACEI/ARB group compared with the ACEI/ARB group (73.7% vs 39.4%, P = .017). No serious adverse events were observed in either group.
Conclusions:
In real-world settings, the finerenone combined with ACEI/ARB regimen significantly improved outcomes in IgAN patients, effectively reducing proteinuria levels and increasing serum albumin levels, while maintaining relatively stable eGFR and exhibiting safety.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion